NeuroOne Medical Tech

Q3 FY2026 EarningsQ3 FY26 results missed consensus on the top line, with revenue of $1.97M vs. $2.55M expected, largely due to manufacturing and shipment timing constraints resulting in a $1.7M backlog. Despite the revenue miss, product gross margin significantly exceeded expectations at 59.9% vs. 53.5% consensus. Diluted GAAP EPS of -$0.28 missed the -$0.22 consensus, primarily driven by higher-than-expected operating expenses and a $0.4M non-cash warrant liability adjustment. FY26 revenue guidance was set at $9.2M-$10.5M, suggesting a strong Q4 recovery if shipment bottlenecks are resolved.